bi 1701963
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Oct 15, 2019 (NCT04111458)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- GTPase KRasINHIBITOR
KRAS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04975256 | Phase 1 | Aug 12, 2021 | Boehringer Ingelheim, Mirati Therapeutics Inc. |
| NCT04973163 | Phase 1 | Aug 3, 2021 | Boehringer Ingelheim |
| NCT04835714 | Phase 1 | Apr 20, 2021 | Boehringer Ingelheim |
| NCT04627142 | Phase 1 | Nov 23, 2020 | Boehringer Ingelheim |
| NCT04111458 | Phase 1 | Oct 15, 2019 | Boehringer Ingelheim |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 5 | 4 | 1 | 2019 |
| Mirati Therapeutics Inc. | For profit | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1